Literature DB >> 29887951

Targeting CAND1 promotes caspase-8/RIP1-dependent apoptosis in liver cancer cells.

Zhihui Che1, Fuchen Liu1,2, Wenli Zhang1, Mary McGrath3, Daisen Hou1, Ping Chen1, Chunhua Song3, Dongqin Yang1.   

Abstract

Cullin-associated NEDD8-dissociated 1 (CAND1) plays a vital role in regulating the activity of Cullin-RING ubiquitin ligases (CRLs), which are frequently dysregulated in cancer. However, the role of CAND1 in hepatocellular carcinoma (HCC) remains unknown. Here, we found that CAND1 was overexpressed in HCC tissues compared to corresponding adjacent liver tissues (71.7% vs 16.7%); high expression of CAND1 was associated with poor overall survival (40.7 vs 57.3 months, P=0.0013); and CAND1 was an independent risk factor for the prognosis of HCC patients (N=138, P=0.018). Functional studies revealed that CAND1 knockdown efficiently suppressed the proliferation of liver cancer cells by activating caspase-8-dependent mitochondrial apoptosis. We also observed a mutual activation loop between caspase-8 and Receptor Interacting Protein 1 (RIP1), which amplified CAND1 knockdown-induced apoptotic signals in the cells. Furthermore, RIP1 inhibitor Necrostatin-1 eliminated the activation of caspase-8. In conclusion, our study pioneered in reporting high CAND1 expression as a predictor of poor prognosis for HCC patients. CAND1 silencing suppressed HCC cell proliferation by inducing caspase-8/RIP1-dependent apoptosis. These findings supported that CAND1 could be a new therapeutic target for liver cancer.

Entities:  

Keywords:  Cullin-associated NEDD8-dissociated 1 (CAND1); Receptor Interacting Protein 1 (RIP1); apoptosis; caspase-8; hepatocellular carcinoma (HCC)

Year:  2018        PMID: 29887951      PMCID: PMC5992550     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  45 in total

1.  RIG-I RNA helicase activation of IRF3 transcription factor is negatively regulated by caspase-8-mediated cleavage of the RIP1 protein.

Authors:  Akhil Rajput; Andrew Kovalenko; Konstantin Bogdanov; Seung-Hoon Yang; Tae-Bong Kang; Jin-Chul Kim; Jianfang Du; David Wallach
Journal:  Immunity       Date:  2011-03-25       Impact factor: 31.745

2.  Distinct roles of RIP1-RIP3 hetero- and RIP3-RIP3 homo-interaction in mediating necroptosis.

Authors:  X-N Wu; Z-H Yang; X-K Wang; Y Zhang; H Wan; Y Song; X Chen; J Shao; J Han
Journal:  Cell Death Differ       Date:  2014-06-06       Impact factor: 15.828

3.  RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex.

Authors:  B A Abhari; S Cristofanon; R Kappler; D von Schweinitz; R Humphreys; S Fulda
Journal:  Oncogene       Date:  2012-08-13       Impact factor: 9.867

4.  Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis.

Authors:  Y Lin; A Devin; Y Rodriguez; Z G Liu
Journal:  Genes Dev       Date:  1999-10-01       Impact factor: 11.361

Review 5.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

Authors:  Jordi Bruix; Maria Reig; Morris Sherman
Journal:  Gastroenterology       Date:  2016-01-12       Impact factor: 22.682

6.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

7.  Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.

Authors:  Jatin J Shah; Andrzej J Jakubowiak; Owen A O'Connor; Robert Z Orlowski; R Donald Harvey; Mitchell R Smith; Daniel Lebovic; Catherine Diefenbach; Kevin Kelly; Zhaowei Hua; Allison J Berger; George Mulligan; Hélène M Faessel; Stephen Tirrell; Bruce J Dezube; Sagar Lonial
Journal:  Clin Cancer Res       Date:  2015-11-11       Impact factor: 12.531

8.  F-box-directed CRL complex assembly and regulation by the CSN and CAND1.

Authors:  Michael W Schmidt; Philip R McQuary; Susan Wee; Kay Hofmann; Dieter A Wolf
Journal:  Mol Cell       Date:  2009-09-11       Impact factor: 17.970

9.  Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation.

Authors:  Young Sik Cho; Sreerupa Challa; David Moquin; Ryan Genga; Tathagat Dutta Ray; Melissa Guildford; Francis Ka-Ming Chan
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

10.  Small molecule perturbation of the CAND1-Cullin1-ubiquitin cycle stabilizes p53 and triggers Epstein-Barr virus reactivation.

Authors:  Nadezhda Tikhmyanova; Steve Tutton; Kayla A Martin; Fang Lu; Andrew V Kossenkov; Nicholas Paparoidamis; Shannon Kenney; Joseph M Salvino; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2017-07-17       Impact factor: 6.823

View more
  3 in total

1.  Epithelial HVEM maintains intraepithelial T cell survival and contributes to host protection.

Authors:  Goo-Young Seo; Daisuke Takahashi; Qingyang Wang; Zbigniew Mikulski; Angeline Chen; Ting-Fang Chou; Paola Marcovecchio; Sara McArdle; Ashu Sethi; Jr-Wen Shui; Masumi Takahashi; Charles D Surh; Hilde Cheroutre; Mitchell Kronenberg
Journal:  Sci Immunol       Date:  2022-07-29

2.  The Impact of Cand1 in Prostate Cancer.

Authors:  Andrea Eigentler; Piotr Tymoszuk; Johanna Zwick; Arndt A Schmitz; Andreas Pircher; Florian Kocher; Andreas Schlicker; Ralf Lesche; Georg Schäfer; Igor Theurl; Helmut Klocker; Isabel Heidegger
Journal:  Cancers (Basel)       Date:  2020-02-12       Impact factor: 6.639

Review 3.  Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer.

Authors:  Jerry Vriend; Mark W Nachtigal
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.